Marksans Pharma (MARKSANS) Stock Overview
Engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
MARKSANS Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Marksans Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹166.53 |
| 52 Week High | ₹358.70 |
| 52 Week Low | ₹162.51 |
| Beta | 1.17 |
| 1 Month Change | -3.75% |
| 3 Month Change | -36.69% |
| 1 Year Change | -42.54% |
| 3 Year Change | 252.44% |
| 5 Year Change | 210.98% |
| Change since IPO | 512.36% |
Recent News & Updates
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
Aug 07Recent updates
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
Aug 15Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
Aug 07Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Jun 28We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
May 27₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
May 22Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
May 14Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Mar 23Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
Mar 05Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
Feb 15Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 01
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Nov 27Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Oct 24Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Sep 21Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Shareholder Returns
| MARKSANS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.3% | -0.7% | -0.6% |
| 1Y | -42.5% | -7.2% | -6.0% |
Return vs Industry: MARKSANS underperformed the Indian Pharmaceuticals industry which returned -7.2% over the past year.
Return vs Market: MARKSANS underperformed the Indian Market which returned -6% over the past year.
Price Volatility
| MARKSANS volatility | |
|---|---|
| MARKSANS Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: MARKSANS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: MARKSANS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,840 | Mark Saldanha | marksanspharma.com |
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids.
Marksans Pharma Limited Fundamentals Summary
| MARKSANS fundamental statistics | |
|---|---|
| Market cap | ₹75.47b |
| Earnings (TTM) | ₹3.50b |
| Revenue (TTM) | ₹26.52b |
Is MARKSANS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MARKSANS income statement (TTM) | |
|---|---|
| Revenue | ₹26.52b |
| Cost of Revenue | ₹11.98b |
| Gross Profit | ₹14.54b |
| Other Expenses | ₹11.04b |
| Earnings | ₹3.50b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.73 |
| Gross Margin | 54.82% |
| Net Profit Margin | 13.20% |
| Debt/Equity Ratio | 12.9% |
How did MARKSANS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 01:25 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marksans Pharma Limited is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Deepika Murarka | Choice Equity Broking Private Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |